Christina Danial1, Andrea L Tichy1, Umar Tariq2, Glenda L Swetman1, Phuong Khuu1, Thomas H Leung1, Latanya Benjamin1, Joyce Teng1, Shreyas S Vasanawala2, Alfred T Lane3. 1. Department of Dermatology, Lucile Packard Children's Hospital at the Stanford University School of Medicine, Palo Alto, California. 2. Department of Radiology, Stanford University School of Medicine, Stanford, California. 3. Department of Dermatology, Lucile Packard Children's Hospital at the Stanford University School of Medicine, Palo Alto, California. Electronic address: alfred.lane@stanford.edu.
Abstract
BACKGROUND: Lymphatic malformations can be challenging to treat. Mainstay interventions including surgery and sclerotherapy are invasive and can result in local recurrence and complications. OBJECTIVE: We sought to assess the effect of 20 weeks of oral sildenafil on reducing lymphatic malformation volume and symptoms in children. METHODS: Seven children (4 boys, 3 girls; ages 13-85 months) with lymphatic malformations were given oral sildenafil for 20 weeks in this open-label study. The volume of the lymphatic malformation was calculated blindly using magnetic resonance imaging performed before and after 20 weeks of sildenafil. Lymphatic malformations were assessed clinically on weeks 4, 12, 20, and 32. Both the physician and parents evaluated the lymphatic malformation in comparison with baseline. RESULTS: Four subjects had a lymphatic malformation volume decrease (1.0%-31.7%). In 2 subjects, despite a lymphatic malformation volume increase (1.1%-3.7%), clinical improvement was noted while on sildenafil. One subject had a 29.6% increase in lymphatic malformation volume and no therapeutic response. Lymphatic malformations of all 6 subjects who experienced a therapeutic response on sildenafil softened and became easily compressible. Adverse events were minimal. LIMITATIONS: A randomized controlled trial will be necessary to verify the effects of sildenafil on lymphatic malformations. CONCLUSIONS: Sildenafil can reduce lymphatic malformation volume and symptoms in some children.
BACKGROUND:Lymphatic malformations can be challenging to treat. Mainstay interventions including surgery and sclerotherapy are invasive and can result in local recurrence and complications. OBJECTIVE: We sought to assess the effect of 20 weeks of oral sildenafil on reducing lymphatic malformation volume and symptoms in children. METHODS: Seven children (4 boys, 3 girls; ages 13-85 months) with lymphatic malformations were given oral sildenafil for 20 weeks in this open-label study. The volume of the lymphatic malformation was calculated blindly using magnetic resonance imaging performed before and after 20 weeks of sildenafil. Lymphatic malformations were assessed clinically on weeks 4, 12, 20, and 32. Both the physician and parents evaluated the lymphatic malformation in comparison with baseline. RESULTS: Four subjects had a lymphatic malformation volume decrease (1.0%-31.7%). In 2 subjects, despite a lymphatic malformation volume increase (1.1%-3.7%), clinical improvement was noted while on sildenafil. One subject had a 29.6% increase in lymphatic malformation volume and no therapeutic response. Lymphatic malformations of all 6 subjects who experienced a therapeutic response on sildenafil softened and became easily compressible. Adverse events were minimal. LIMITATIONS: A randomized controlled trial will be necessary to verify the effects of sildenafil on lymphatic malformations. CONCLUSIONS:Sildenafil can reduce lymphatic malformation volume and symptoms in some children.
Authors: J L Faul; G J Berry; T V Colby; S J Ruoss; M B Walter; G D Rosen; T A Raffin Journal: Am J Respir Crit Care Med Date: 2000-03 Impact factor: 21.405
Authors: Jennifer J Marler; Steven J Fishman; Susan M Kilroy; Jianmin Fang; Joseph Upton; John B Mulliken; Patricia E Burrows; David Zurakowski; Judah Folkman; Marsha A Moses Journal: Pediatrics Date: 2005-07 Impact factor: 7.124
Authors: Adrienne M Hammill; MarySue Wentzel; Anita Gupta; Stephen Nelson; Anne Lucky; Ravi Elluru; Roshni Dasgupta; Richard G Azizkhan; Denise M Adams Journal: Pediatr Blood Cancer Date: 2011-03-28 Impact factor: 3.167
Authors: Jo Nadine Fleming; Sirkka Liisa Hostikka; Eunice Y Chen; Stephen M Schwartz; Jonathan A Perkins Journal: Otolaryngol Head Neck Surg Date: 2008-11 Impact factor: 3.497
Authors: June K Wu; Ellen D Hooper; Sherelle L Laifer-Narin; Lynn L Simpson; Jessica Kandel; Carrie J Shawber Journal: Pediatrics Date: 2016-08-25 Impact factor: 7.124